OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test – Yahoo Finance
BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research and Development Authority (BARDA) has issued the Company an $8.6 million contract to develop a 2nd generation Ebola test on the OraQuick® testing platform. The goal is for the 2nd generation test to have improved sensitivity, increased shelf life, new chemistry and more automation when compared to the de novo U.S. Food and Drug Administration (FDA) authorized test. OraSure’s OraQuick® Ebola Rapid Antigen test is the only test today with a de novo authorization from the FDA and has been used extensively for Ebola cadaver testing in Africa with results available in 30 minutes.
“We are proud to partner with BARDA to develop a 2nd generation Ebola test and help prevent the spread of a disease which impacts some of our most vulnerable global communities,” said Lisa Nibauer, President of Diagnostics for OraSure Technologies. “Whether it be our response to the HIV epidemic, our work to counter the global COVID-19 pandemic, or this project, OraSure has increasingly partnered with the United States Federal government to counter some of the largest public health challenges we face across the globe.”
OraSure’s current OraQuick® Ebola Rapid Antigen Test is de novo authorized for use with whole blood or cadaveric oral fluid. The test received de novo authorized from the FDA in 2019, making it the first and only rapid antigen test to receive authorization for the detection of Ebola virus.
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50122R00024.
About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
Important Information
This press release contains certain forward-looking statements, including with respect to the Company’s products, product development activities, regulatory submissions and authorizations and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: risk that the Company’s exploration of strategic alternatives may not result in any definitive transaction or enhance stockholder value and may create a distraction or uncertainty that may adversely affect operating results, business or investor perceptions; the diversion of management’s attention from the Company’s ongoing business and regular business responsibilities due to the Company’s exploration of strategic alternatives; ability to resolve the Company’s ongoing manufacturing challenges and satisfy customer demand; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on the Company’s business and ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
Investor Contact:
Media Contact:
Scott Gleason
Amy Koch
SVP Investor Relations & Corporate Communications
Sr. Mgr. Corporate Communications
484-425-0588
484-523-1815
sgleason@orasure.com
media@orasure.com
Related Quotes
Wall Street is on a roller coaster again, as investors try to navigate the path between high inflation and the Fed’s aggressive interest rate hikes. The former is raging – whether you blame Russia or Biden, the fact of high inflation can no longer be avoided – while the latter is rising – but whether it is rising fast enough to blunt inflation is yet to be determined. Jim Cramer, the well-known host of CNBC’s ‘Mad Money’ program, takes a hint from the bond market, where the US Treasury 2-year no
Top trending stocks in after hours trading on Wednesday, September 28, 2022.
The CBOE Volatility Index has skyrocketed 89% so far this year. Morningstar put together a list of stocks with one- and three-year betas of 0.8 or lower. Then it screened for stocks that are undervalued, according to Morningstar analysts' fair value estimates.
Analysts are either optimistic or delusional. But either way, they see a big S&P 500 29% rally coming — and have picked favorite stocks.
The current cap on yearly buys of I bonds is $10,000 per person plus $5,000 through federal tax refunds. Two senators propose raising that limit to $30,000 in total.
Anyone following stock market trends in 2022 will be well aware of the widespread drawbacks; apart from some outliers such as energy, most corners of the market have been beaten to a pulp. The main culprits are easily identified by now; a combination of a slowing economy, rampant inflation, rates hikes to halt it, and Russia’s invasion of Ukraine and the global implications are all responsible factors. Stock market giants have not been immune either and many have seen huge chunks of their valuat
Marijuana stocks continued to rebound from last week's sell-off on Wednesday, with shares of Canopy Growth (NASDAQ: CGC) gaining 4.2%, Tilray Brands (NASDAQ: TLRY) up 4.8%, and Aurora Cannabis (NASDAQ: ACB) leading the whole pack higher with a 5.4% gain as of 1:40 p.m. ET. The Nasdaq — to which index all three of these cannabis stocks belong — is up 1.5% in midafternoon trading. This morning, Canopy announced that in an effort to progress from losses toward profitability, it will divest its Canadian Tweed and Tokyo Smoke retail operations and focus in the future on producing "premium" branded cannabis as a consumer packaged goods company.
(Bloomberg) — Some big bond investors say don’t be deceived by the Treasury market’s torrid rally Wednesday. The hawkish signals still coming out of the Federal Reserve are what matters. The rest is noise. The world’s biggest bond market has been whipsawed in recent days on the back of a debt crisis gripping the UK. Benchmark 10-year Treasuries tumbled by the most since the Covid crash on Monday, only to rebound just as quickly on Wednesday when the Bank of England stepped in to buy gilts and s
Yahoo Finance Live checks out Netflix's shares after Atlantic Equities upgrades the company's stock to "Neutral" and the streaming platform announces plans to limit password sharing.
Earlier this week, the Dow Jones joined the S&P 500 and the NASDAQ in bear market territory. It marks the first time this year that the Dow has dipped below a 20% loss from peak – but it also marks a turning point in investor sentiment. A mood of doom and gloom is setting in. A change in times and a change in mood requires a change in outlook, a shift in perspective, for investors to succeed. With all three main indexes so far down, it’s clear that the last year’s modes of trading aren’t going t
Shares of beaten-down big tech stocks Nvidia (NASDAQ: NVDA), Meta Platforms (NASDAQ: META), and Palantir Technologies (NYSE: PLTR) bounced back today, rising 2%, 3.4%, and 2.8%, respectively, as of 11:34 a.m. ET. There wasn't much company specific news from these three today, but their shares being down so much on the year already, combined with some marginally favorable news this morning on interest rates and geopolitics, was enough to get their stocks moving higher. Equity investors may not have noticed, but Treasury Bond yields may be determining your stock portfolio performance this year more than you think — especially when it comes to technology growth stocks.
The major indexes rebounded as Treasury yields tumbled from 4% as the Bank of England resumed bond buying. Eli Lilly led stocks showing bullish action. Here's what to do now.
NIO Inc. (NIO) closed at $17.33 in the latest trading session, marking a +0.81% move from the prior day.
In this article, we discuss 11 best dividend-paying stocks to buy now. You can skip our detailed analysis of dividend stocks and their returns, and go directly to read 5 Best Dividend Paying Stocks To Buy Now. Dividend companies are gaining ground among investors this year as they navigate the rocky market. In times of financial […]
The super investor isn't thrilled with the Fed. But she's still bullish.
The stock market had a good trading session on Wednesday, but Rivian Automotive (NASDAQ: RIVN) had a really good day. RBC Capital Markets' Joseph Spak made the move in a new research note that morning, slicing his level to $62 per share from the previous $75. Spak is mainly concerned with Rivian's aim to switch over from rail to truck delivery.
Boyar Research's Jonathan Boyar joins Yahoo Finance Live to discuss low stock valuations, the stock market, and his stock picks in the financial and tech sectors.
Yahoo Finance Live anchors discuss reports that Apple has ditched plans to increase iPhone 14 production.
As a case in point, Buffett owns more stocks than you'll find listed in Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) regulatory filings. You might even say that Buffett has a "secret portfolio." Berkshire's acquisition of General Re years ago brought New England Asset Management (NEAM) into its fold.
ZIM Integrated Shipping Services (ZIM) closed at $25.39 in the latest trading session, marking a +1.68% move from the prior day.